Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry everyone , I'm no expert with the internet as I have tried unsuccessfully posting their recent success story posters on here. I will try posting them again.
There is a huge potential growth financially for FLTT as they are investing heavily in money transfer worldwide and competing aggressively to Western Union to markets in Southeast Asia/ Asia such as VietNam, India etc...in remittance. Anticipating good news comes out from Ficombank when they submit their fourth quarter income report (2011) sometime this month (3/2012)
I'm not a financial advisor. All of my posts are for entertainment purposes only and based on my opinion. Please do not buy based on my recommendations, do you own DD.
Connect2family
[img][/img]
Viet Nam
Quang Nguyen – Chief Marketing Officer
Mr. Quang Nguyen has over 20 year experience in developing multiple successful business ventures in Australia and Vietnam, through his business venture Mr. Quang has introduce several products and services to complement both Australian and Vietnamese market.
Mr. Quang Nguyen has established well connected network with Vietnamese Community in all three countries through his successful business ventures in Vietnam. He has managed several companies including Golden Connect as a Managing Director and these ventures include natural resource opportunities and in consumer goods. He also provides business advisory, international trading, M&A support and pairing business opportunities among companies both within and outside Vietnam.
Through its relationships in the Vietnamese communities in Australia and the USA, Mr. Nguyen will lead the marketing activities through Vietnamese organizations and the commercial communities in these countries. Mr. Nguyen has B.Sc. degree in Applied Science from South Australian Institute of Technology and also Immigration Law from Australian National University, Canberra, Australia.
India to see highest foreign remittances in 2011: World Bank (USD 58 billion)
NEXT- IMO
Abu Karim – Chief Executive Officer
Mr. Abu Karim has a combined role; CEO, Remit2Vietnam and President - Australia/NZ, Asia Pacific, Ingedigit International Inc., providing him access to wealth of expertise from both organisations for successful implementation of the prepaid card program in USA and Australia. He has been working closely with the executive team at Remit2Vietnam for the past year in developing this market opportunity. Abu is responsible for the development of pre-paid card programs for the past 5 years across Asia Pacific region including Gulf Cooperative Councils (GCC).
Mr. Karim has 23 year experience in sales, marketing and management providing solutions to Australia and Asia Pacific markets for both financial and retail sectors, which included working for IBM and NCR. Mr. Karim has B.Sc. degree in Mechanical Engineering from University of Lowell, Massachusetts, USA.
http://www.r2v.com.au/#/the-management-team/4550080008
Huge future..........IMO
Lowest Cost MasterCard and Money Transfers to Vietnam
All in One Card, For You and Your Family
Who is Connect2Family?
· Connect2Family is an international Card and Money Transfer company registered in the USA and Australia specializing in low cost payment services.
· Connect2Family USA Inc. is an Independent Sales Organization ("ISO") pursuant to an agreement with The Vista Bank.
· Connect2Family USA Inc is an Independent Sales Organization ("ISO") pursuant to an agreement with MasterCard International Incorporated
What is the Connect2Family™ Prepaid MasterCard and How Does it Work?
The Connect2Family Prepaid MasterCard is a prepaid, reloadable MasterCard that gives you a safe and easy way to manage spending for yourself or the people you choose. An adult 18 years of age or older can purchase the Connect2Family™ Prepaid MasterCard. The Card Purchaser loads the Card with funds upfront and can reload it so that the Connect2Family Prepaid MasterCard
How does the Connect2Family™ Prepaid MasterCard work?
The Card is easy to use - just load, spend, repeat.
1. LOAD Add money online or by phone from a bank account OR with cash at any Connect2Family™ or EmpaSys agent.
2. SPEND You, or the people for whom you've bought the Card, can use the Card at millions of locations around the world: in stores, online, and at ATMs.
3. REPEAT You can reload the Card as often as you wish either online or in Connect2Family’s Merchant. Plus, you and the people for whom you've purchased the Card can set up an online account to check the Card balance, view transactions and set up alerts.
Is the Connect2Family™ Prepaid MasterCard safe?
The Connect2Family™ Prepaid MasterCard is issued by The Vista Bank pursuant to a license by MasterCard International Incorporated and can be used wherever MasterCard is accepted. The Connect2Family Prepaid MasterCard is FDIC insured up to $250,000.
What are the Unique Features of the Connect2Family™ Prepaid Debit MasterCard?
· Lowest cost Prepaid Debit MasterCard in the USA
· Lowest cost, bank guaranteed, instant money transfer to Vietnam
· Card to Phone prepaid international airtime accessed from your Connect2Family™ Prepaid Debit MasterCard
· Link to up to three bank accounts in VietNam
· Link to up to three subsidiary cards in USA
QUESTIONS ABOUT REMITTANCE FROM OVERSEAS TO VIETNAM
How do I use the Connect2Family™ Prepaid Debit MasterCard to remit money to Vietnam?
Buy a Connect2Family™ Prepaid Debit MasterCard at any Connect2family Money Centre agent or from the Connect2Family™ web site
List the bank accounts of up to three people in Viet Nam that you wish to send money to from your card. The accounts can be with any bank and do not need to be with the same bank.
Transfer money to any or all of the people at any time at a Connect2Family™ money centre, any EmpaSys agent or from the Connect2Family™ web site and your relative can receive money instantly in their bank account in Viet Nam.
Which foreign currency I can remit?
You can remit to Vietnam by USD and chose for them to collect in either USD or Dong
Does the beneficiary need to have account in Viet Nam to receive money?
Yes the beneficiary needs to have account in Viet Nam. In case the beneficiary has not opened account in Viet Nam, you can register their name, contact address and then complete their details once they have opened a bank account. Alternatively you can supply their details to Connect2Family and a Connect2Family™ partner bank in Viet Nam will contact them to assist in opening an account.
How long does it take the beneficiary receive money?
The beneficiary can receive money into their bank account in Viet Nam instantly after you remit if they have an account with Saigon Commercial Bank (formerly FICOM Bank, Saigon Commercial Bank Joint Stock Bank and Tin Nghia Bank) or within 1 hour with any other bank in VietNam.
Will beneficiary have to pay tax when he/she receives money in Viet Nam?
· No
How can I know the situation of the remitted funds?
To know the situation of the remitted money in the detail you can check online at www.Connect2Familyusa.com. Or check with any Connect2Family™ Money Centre agent. It does not need to be the agent that you used to remit the funds.
QUESTIONS ABOUT RECIVING MONEY IN VIETNAM
How does the recipient get their funds in Viet Nam?
Funds will be deposited into the recipient account and can be withdrawn at a branch, withdrawn from an ATM if they have an ATM card or if they have a debit card from their bank can be used in a retail merchant or business who has a payment terminal.
What is the remittance fee when the beneficiary receives funds in their Viet Nam bank account?
· No fees charged
What foreign currency can they receive?
Either USD or Dong depending on what currency you have chosen when you transfer the funds.
What exchange rate will be applied?
The exchange rate to be applied by the Viet Nam banks will be advised daily and displayed at the time of transfer on the Connect2Family™ web site or on the screen at the Connect2Family™ Money Centre agent before the transfer is made.
The best remittances for vietnam right now that is safe and fast.
For international funds transfers cheap than Webster Union.IOM
International FundsTransfers
Connect2Family™ provides two choices for fast bank guaranteed international money transfers.
1. Card to Account-$5 regardless of the amount transferred
This is a service of the Connect2Family™ Prepaid MasterCard which provides the facility to:
Load funds to your Connect2Family™ Card
Register up to 3 family member bank accounts in Vietnam (and other countries soon)
Transfer funds direct to the family member’s account in any bank in VietNam
This service is charged at a fixed fee of just $5- regardless of how of the funds transferred or how much is transferred.
There is no foreign exchange mark-up.
The family member can withdraw the funds immediately in Vietnam-with no charges to pay at the bank. If the family member has a card issued by their bank in Vietnam they can also access their funds from an ATM at any time or use their debit card for purchases.
You can chose to send funds as US dollars or as Dong.
Federal authorities govern the amount and frequency of funds that can be sent but currently this amount is a maximum of $1,500 at a time with a monthly maximum of $5000.
You can make transfers either from the Connect2Family™ web site or at any of the Connect2Family or EmpaSys retail agents’ locations.
Click here for a full list of billers and retail merchant partners by ZIP Code
2. Cash To Cash- $10 regardless of the amount transferred
Cash To Cash provides you with a service to send money to almost any country in the world (including Vietnam) but unlike the Connect2Family™ Prepaid MasterCard the money is sent to an agent-usually a bank, where your recipient collects the funds that you have transferred. When you are transferring the funds you can chose a pick up location that is most convenient to your recipient. Depending on the country this service takes between 1 and 3 days.
The good news is that this service is low cost and bank guaranteed.
This service is charged at a fixed fee of $10 and there is no foreign exchange mark-up
Funds are sent in US dollars but received in the receiving country’s currency
Federal authorities govern the amount and frequency of funds that can be sent but currently this amount is a maximum of $1,500 at a time with a monthly maximum of $5,000.
You can make transfers at any of the Connect2Family or EmpaSys retail agents’ locations.
http://preview.86solutions.com/connect2family/?page_id=3096
Remittances to vietnam
Remit2Vietnam
http://www.r2v.com.au/#/news/4550080681
Connect2Family
http://preview.86solutions.com/connect2family/?cat=36
Consolidation of the First 3 banks, Tin Nghia and Saigon
http://ebank.vnexpress.net/gl/ebank//thi-truong/2011/12/hop-nhat-3-ngan-hang-de-nhat-tin-nghia-va-sai-gon/
Boss chair Ficombank bank consolidation
http://ebank.vnexpress.net/gl/ebank/thi-truong/2011/12/sep-ficombank-lam-chu-tich-ngan-hang-hop-nhat/
Ficombank bank
http://www.scb.com.vn/vietnam/default.aspx
Commercial banks have recently launched attractive services and promotion campaigns which aim to attract kieu hoi. Ficombank, for example, has signed a cooperation agreement in providing remittance services with Remit2Vietnam (R2V, Australia). R2V will serve as the unit that receives money remitted to Vietnam from the Vietnamese people who live, work and study in the US, Australia and Canada.
Commercial banks report good overseas remittance this year
http://english.vietnamnet.vn/en/business/10716/commercial-banks-report-good-overseas-remittance-this-year.html
Remittance Growth Highlights Opportunity for Prepaid
February 6, 2012
By: William Cain
VRL provides independent incisive analysis and insight for the global cards and payments community.
https://www.partnersinprepaid.com/topics/articles/remittance%20growth%20highlights%20opportunity%20for%20prepaid.html
Viet Nam: Remittances set to reach $9b in 2011
http://remittancesgateway.org/index.php/press-clippings/flows-information/1073-viet-nam-remittances-set-to-reach-9b-in-2011
I'm not a financial advisor. All of my posts are for entertainment purposes only and based on my opinion. Please do not buy based on my recommendations, do you own DD.
Total annual sales of propofol in the U.S. is about $500 million.
APP Pharmaceuticals is the only one company to supply propofol to the entire U.S. market
http://www.outpatientsurgery.net/news/2010/06/3-no-relief-for-propofol-shortage
Home > News > June, 2010
No Relief for Propofol Shortage
Supply problems continue amid fresh recalls and the loss of one major manufacturer.
Categories: Anesthesia, Product Reports, News
An "ongoing and long-term problem." That's how the FDA characterized the U.S. propofol shortage back in March, and in the past week, the problem appears to have gotten much worse, as Teva Pharmaceuticals announced it would cease making propofol and Hospira recently issued a fresh recall of the sedative.
Teva stopped manufacturing propofol in mid-April, formally decided not to re-enter the market on May 26 and currently is not shipping any propofol, says Denise Bradley, Teva's senior director of North American corporate communications. The decision was a financial one: "Ultimately, it is because the product in its current formulation is difficult to manufacture and has little to no profitability."
Because of the recent shortage, which has thrown the propofol market off-balance, Ms. Bradley says she's not sure what Teva's most recent share of the market has been, but the company estimates that it has historically supplied about 40% of the nation's propofol.
Since manufacturing problems at both Teva and Hospira, the 2 major U.S. suppliers of generic propofol, disrupted the market last year, European manufacturer APP "has been covering the majority of the market," says Crystal Rice of the FDA's Center for Drug Evaluation and Research. Ms. Rice says the FDA is working with APP to further increase supplies, "and Hospira is also working to return to the market as quickly as possible."
A spokesman for Hospira confirms that the company has improved its manufacturing process for propofol and resumed production, but hasn't released any new propofol yet because the FDA is still reviewing its manufacturing changes. "We will release the product once we have the agency's approval," he says. "We can't speculate on the timing."
Meanwhile, just this week Hospira announced it was expanding a voluntary recall of certain lots of propofol injectable emulsion 1%, as well as Liposyn intravenous fat emulsion, saying that "some of the containers may contain particulate matter made up of sub-visible inert stainless steel particles." The recall, which began March 31 and was expanded this week, affects propofol lots beginning with numbers 66 through 78, and 82 through 85.
See the American Society of Health-System Pharmacists' website and the FDA's Current Drug Shortages page for updates on the availability of propofol. Contact the FDA's Drug Shortage Program at drugshortages@fda.hhs.gov with questions or concerns about obtaining anesthetics in short supply.
Irene Tsikitas
http://www.anesthesiologynews.com/ViewArticle.aspx?d=Web+Exclusives&d_id=175&i=May+2010&i_id=633&a_id=15211
Teva Exits Propofol Market
Move, which leaves two U.S. suppliers, seen exacerbating ongoing shortage
by Adam Marcus
For those who thought the nearly yearlong propofol shortage couldn’t get any worse, here’s a dose of added unpleasantness:
Teva Pharmaceutical Industries, a leading domestic manufacturer of the sedative, has told the FDA that it will stop producing the product. The decision, which comes on the heels of a $356 million jury award involving use of the company’s drug in Nevada, means that the shortage of propofol likely will become even more aggravating for clinicians, experts said.
Propofol has long been the injected anesthetic of choice in hospitals for both surgery and intensive care applications, and the loss of Teva’s product from the market leaves only two U.S. companies, APP Pharmaceuticals (Diprivan) and Hospira, producing the medication in the United States. However, Hospira has had its own troubles with propofol and has not been shipping the product for more than two months. Denise Bradley, a spokeswoman for Teva, said the decision to stop producing propofol was financial. “The product is difficult to manufacture and has little to no profitability.”
Ms. Bradley said Teva, which hasn’t been making or shipping propofol since mid-April, has not determined what product it will manufacture in the Irvine, Calif., facility where the company produced the sedative.
“We are aware that Teva has announced its discontinuation of propofol,” said Crystal Rice, an FDA spokeswoman. “We continue to work actively with the remaining two manufacturers, APP and Hospira, to ensure that adequate supplies of the drug are available. APP has been covering the majority of the market and we are working with them on increasing supplies further, and Hospira is also working to return to the market as quickly as possible.”
Teva and Hospira have been plagued by manufacturing difficulties since last July that curtailed stocks of propofol by 25% or more. In late 2009, the FDA allowed APP, a division of the European firm Fresenius Kabi Group, to import a version of propofol to ease the shortage. That product, Propoven, has a slightly different chemical makeup from domestic formulations of the drug, but is thought to act similarly in the body.
Despite that decision, hospitals continue to complain of problems with obtaining adequate supplies of propofol. As a result, many anesthesiologists have been forced to switch to alternative sedatives with which they may have less experience. However, supply woes also have affected several other anesthesia-related drugs, including thiopental (Pentothal, Hospira) and certain neuromuscular blocking agents.
A Year's Worth of Problems
Teva’s woes began in mid-July, when the company recalled lots of propofol after at least 20 patients who received the drug fell ill with flu-like symptoms. The company announced that it had discovered high levels of endotoxin in vials of the sedative pulled from the affected lots.
In October, Hospira notified customers that it was recalling batches of propofol and Liposyn, an IV fat emulsion with which propofol is administered, after discovering metal particles in the products.
Hospira eventually restarted production, but in March it recalled its propofol shipments and stopped producing the drug when metal particles were once again detected in the medication.
Daniel Rosenberg, a Hospira spokesman, said the two recalls involved unrelated equipment and manufacturing problems and that it was unclear when the company would resume selling the drug.
“We have made improvements to the manufacturing process for propofol and have begun manufacturing again. However, we haven't released the newly manufactured product because our manufacturing changes are being reviewed by the FDA,” Mr. Rosenberg said. “We will release the product once we have the agency’s approval. We can't speculate on the timing.”
Mr. Rosenberg said Hospira has received no reports of patient harm linked to the glitches.
Teva’s plans to stop making propofol were first reported by the Wall Street Journal. The company could not immediately be reached for comment.
Early this month, a jury in Las Vegas awarded Henry Chanin $500 million in a verdict against Teva and Baxter Healthcare, whom it had previously found guilty of product liability issues surrounding propofol. Mr. Chanin had contracted hepatitis C during an endoscopic procedure for which he received propofol administered through a re-used syringe. The two companies are appealing the judgment.
Ms. Bradley said Teva’s decision “has nothing to do with the Las Vegas trial. That situation was a case of blatant disregard of product labeling.”
Favorable Profile of Action and Safety Makes Replacing Drug Difficult
Marc E. Koch, MD, MBA, president and CEO of Somnia Inc., a major group anesthesia practice based in New Rochelle, N.Y., said the loss of a supply of propofol “creates a problem” for all anesthesiologists regardless of where they work. “Very few medications are quick on/quick off and have almost no side effects,” Dr. Koch said.
For those reasons, Dr. Koch estimated that between “95% to 100%” of the roughly 250,000 anesthetics Somnia clinicians perform each year involve propofol. Now, he added, clinicians may have to resort to barbiturate-based agents with less favorable profiles. “It’s going to be a really tough period for all anesthesia providers,” he said.
Bona E. Benjamin, RPh, director of medication-use quality improvement for the American Society of Health-System Pharmacists (ASHP), called the loss of Teva’s propofol “concerning” and said hospitals could feel the effects in their coffers.
“ASHP surveyed members in late April on budget implications,” Ms. Benjamin said. “Over 80% responded that the shortage had increased costs ‘somewhat’ or ‘significantly.’ Some pharmacy departments are preparing propofol in ready-to-administer doses for anesthesia, an extremely labor-intensive process due to the short beyond-use dating of propofol,” she said. “So, yes, budgets are adversely affected."
Some hospitals and anesthesia groups also have reported price gouging on the part of suppliers, who have taken advantage of short supplies to raise the price on propofol. Dr. Koch, for example, said his company had paid 10 times the usual price for the drug, although he stopped short of calling the hike a gouge.
“I am highly concerned about the prospects of losing Teva as a manufacturer of propofol,” said Tricia A. Meyer, PharmD, MS, director of the Department of Pharmacy and assistant professor of anesthesiology at Scott and White Hospital at Texas A&M Health Science Center, in Temple. “When we were struggling to cope with propofol supply disruptions over the past few months, we used all three current suppliers—Teva, Hospira and APP. If one company had shortages, we’d attempt to order from the others to fill the gap. Now, with Teva pulling out, that flexibility will be gone.”
Dr. Meyer said that Teva's decision to stop manufacturing propofol will severely erode her hospital's flexibility in purchasing the sedative. Such flexibility, she stressed, is crucial for a drug that is “one of the most frequently used products in any hospital—it’s widely used not only in the operating room and in ambulatory surgery, but also in the emergency department and particularly in the ICU.”
Having access to multiple suppliers also provides an important hedge against drug shortages related to FDA sanctions.
“If one plant has a manufacturing issue—as Teva did in 2009—that may cause a supply disruption,” Dr. Meyer said. In these cases, “it helps to have other suppliers available." Having Teva out of the market, she noted, limits a hospital's ability to turn to alternative sources "and may extend the current propofol shortage or potentially even make it worse.”
Dr. Meyer urged Teva “to consider the practitioner” when devising a plan for leaving the propofol market. “I would like to see Teva work closely with FDA and the other propofol suppliers to ensure a smooth transition, with steps taken to ensure adequate supplies of [the sedative] for health care providers,” she said. “This may be a six- to eight-month transition period.”
Ms. Bradley said Teva did consider the needs of clinicians, but ultimately chose to bow out of the market for propofol. “We do understand clinician concerns, but felt we could not manufacture this product any longer,” she said.
Additional reporting by David Bronstein.
http://www.medscape.com/viewarticle/720862
Why is there a propofol shortage in a free market?
5 comments
August 27, 2010 at 8:00 am Aaron Carroll
A longtime reader (Austin says so) emails us:
This NEJM article relates the sustained problem we have had obtaining a key drug, Propofol. I can understand how we end up with drug companies not wanting to make orphan drugs. Even after reading this article, it remains unclear why someone would not want to produce such a highly used medication. The price should go up, and producers respond by making more. This is not happening. Why arent markets working?
Well, I’m not an economist, but I think this is an example of a “perfect storm”. Here is a small piece from the FDA-written NEJM piece:
Recently, the supply of one drug — the sterile injectable drug propofol, a fast-onset, short-acting sedative–hypnotic agent used for the induction and maintenance of anesthesia or sedation — has become critically low. In 2009, there were three manufacturers making propofol: Teva Pharmaceuticals, Hospira, and APP Pharmaceuticals. In early October 2009, Hospira recalled multiple batches of its propofol owing to the presence of particulate matter in the vials. In late October 2009, Teva recalled multiple lots of its propofol owing to possible microbial contamination. As of May 2010, Hospira had not yet returned propofol to the market and had expanded its recall to capture all product that might currently be in customers’ inventories, and Teva recently announced that it would not be returning to the market. This confluence of events has left only one company to supply propofol to the entire U.S. market — an unrealistic expectation, given anesthesiologists’ reliance on the drug.
Let’s recap. Propofol is an excellent drug for anesthesia. It starts working really fast, and its effects go away really fast when you stop adding it. That’s exactly what you want. But there are a number of factors that make it unappealing:
Propofol is relatively difficult to produce.
Propofol gets contaminated easily in use, as it has no preservatives.
Propofol is generic, and therefore the price is lower than on patent drugs. So it’s hard to make money.
In general, sterile injectables are especially prone to shortages because of these reasons. As the NEJM piece notes:
Although shortages can occur with any drug, sterile injectable drugs such as propofol are particularly susceptible. Data collected by the Drug Shortage Program of the Food and Drug Administration (FDA) show that of 110 shortages that occurred in 2008, 39 involved sterile injectables (35%), and in 2009, the proportion rose to 73 of 157 drug shortages (46%).
Some time ago, three companies made propofol: Teva Pharmaceuticals, Hospira, and APP Pharmaceuticals. But starting last October, the dominoes began to fall. First, Hospira was forced to recall multiple batches of its drug because of contaminants in vials. Soon after, Teva was forced to recall multiple batches of the drug because of possible microbial contamination. Instead of recovering, things got worse. Six months later, Hospira was still recalling the drug and was not bringing any new propofol to market.
And then, in May, a Jury awarded a $500 million verdict for the first (of many) civil cases concerning a Hepatitis C outbreak linked to propofol use in a Las Vegas GI endoscopy center. Teva took the brunt of that that verdict. Faced with that massive payout, and more likely on the way, Teva bowed out of the propofol market. Baxter (which merges with Hospira distributed the propofol) was also slapped with a nine-figure verdict in that trial, so it’s unlikely they will be bringing propofol back soon either.
That leaves only one company making all the propofol for the US. That’s not enough. We’ve got a shortage.
Our reader asks why the market failed. I’m not sure it’s possible it could succeed here. Sure, the remaining company could charge a fortune for the drug, but that won’t end the shortage. And other companies aren’t likely to enter the field because it’s so hard to make and they would be open to the same dangers that Teva and Hospira/Baxter faced. It’s just not a risk that I can see pharmaceutical companies taking, when they can make money in much less risky areas.
What should we do? I don’t have a good answer. I’ve seen the usual snark wondering how long it will be until “Obama determines that access to propofol is a right and forces Teva to initiate production”. Teva is an Israeli company (many pharmaceutical companies are foreign corporations) so that’s not going to happen. I expect that as we are forced to import replacement drugs from foreign markets we will hear the usual scare stories (ignoring that it was contamination in US-imported drugs that started all of this). Some will blame the laywers, and some will blame the doctors, and some will blame the companies.
But the truth of the matter is that these types of drugs are not going to get any more profitable or enticing to make. So how should we move forward in a non-socialist solution? I’m looking at you, free marketeers…
Charlie Church Mouse-Kindergarten (PC)
http://reviews.walmart.com/1336/12311463/charlie-church-mouse-kindergarten-pc-reviews/reviews.htm
Too bad for me.....Bought 1.05 .Thanks
Bad new or good new?????
Degama Software Solutions, Inc. (Public, PINK:DGMA)
Description
Degama Software Solutions, Inc., formerly CNTV Entertainment Group. Inc, is the holding company for Beijing Multimedia Limited. Beijing Multimedia partly owns CITIC Cultural & Sports Industry Co. Ltd. CITIC Cultural's principal businesses include film production and distribution, television drama and program production and distribution, subway and railway advertising, magazine and newspaper publication and sports and entertainment businesses.
Officers and directors
Joseph J. Meuse Chairman of the Board, President, Treasurer, Secretary
Patrick Ma Director
Shawn Mak Director
Kwok Hung Lau Director
Bing Hu Director
Jeffrey S. Hall Director
SUMMARY
Name Age Since Current Position
Meuse, Joseph 40 2008 Chairman of the Board, President, Treasurer, Secretary
Ma, Patrick 2004 Director
Mak, Shawn 2004 Director
Lau, Kwok Hung 63 2004 Director
Hu, Bing 2004 Director
Hall, Jeffrey 2008 Director» Insider Trading
BIOGRAPHIES
Name Description
Meuse, Joseph Joseph Meuse is Chairman & President ,Treasurer and Secretary of CNTV Entertainment Group, Inc.He has been involved with corporate restructuring and reverse mergers since 1995. He is a Managing Partner of Castle Capital Partners since 1995 as well as at Belmont Partners since 2003. Additionally, Mr. Meuse maintains a position as a Board member of the following corporations: Network Capital, Inc, Pivotal Technologies, Inc., Niagara Systems, Inc., Retail Holdings, Inc., NuOasis Laughlin, Inc., Big Red Gold, Inc., PacWest Transfer LLC, Global Filings LLC, First Heroes, Inc., Adrenaline Nation Media Networks, Inc. and Media Network. Mr. Meuse attended the College of William and Mary.
Ma, Patrick
Mak, Shawn
Lau, Kwok Hung
Hu, Bing
Hall, Jeffrey Mr. Hall has twenty years' experience in large, medium, small publishing/media companies: he has managed divisions of major corporate, publishing and advertising firms and started two successful publishing businesses. Mr. Hall is a former White House Fellow, with degrees from Stanford University (BA, Communications) and Harvard Business School (MBA). Since 1991, Mr. Hall has served as President, CEO, editor and publisher of the Brentwood Media Group, a Los Angeles based community newspaper publishing company that produces the highly regarded Brentwood News, Bel-Air View, Santa Monica Sun, Palisades 90272, Beverly Hills 90210 and Westside Today, with a combined readership of over 150,000. From 1988 thru 1999, Mr. Hall served as President of the Los Angeles Times, Valley and Ventura County Editions, where he managed all business operations for two regional editions of the Los Angeles Times in a highly competitive environment, with a circulation in excess of 250,000 readers; with over 1000 employees and over $100 million in annual revenues. As a direct result of Mr. Hall's efforts this division of the Los Angeles Times showed market-share gains in the region for the first time in ten years.
BASIC COMPENSATION
Name Fiscal Year Total
Meuse, Joseph --
Ma, Patrick --
Mak, Shawn --
Lau, Kwok Hung --
Hu, Bing --
Hall, Jeffrey --As Of
OPTIONS COMPENSATION
Name Options Value
Meuse, Joseph 0 0
Ma, Patrick 0 0
Mak, Shawn 0 0
Lau, Kwok Hung 0 0
Hu, Bing 0 0
Hall, Jeffrey 0 0
Address
360 Main Street, P O Box 393
Washington, VT 22747
United States - Map
+1-540-6753149 (Phone)
http://www.google.com/finance?q=PINK:DGMA
Hillard Herzog President & CEO Bergamo Acquisition Corp.
Tomorrow.............Tomorrow.......
Hope and hope everyday........No choice.............
GLTA!!!!!!!!!!
Absolutely hang on
I have no choice, stuck in stupid stock,Down 88%,Hope and hope everyday
GLTA!!!!!!!!!!
Hope and hope everyday then nothing new.This one is scam,HH lying,BGMO dead, we're dead